Methods and compositions for treating amyloid-related diseases

A compound of Formula V:

• wherein:
• A is nitrogen or oxygen;
• R11 is hydrogen, salt-forming cation, ester forming group, or when A is nitrogen, A and R11 taken together form the residue of a natural or unnatural amino acid or a salt or ester thereof, wherein A and R11 taken together are not a leucine residue;
• n is 3 or 4;
• aa is an amino acid residue selected from a natural amino acid residue selected from the group consisting of phenylalanine, tyrosine, or an unnatural amino acid residue selected from the group consisting of para-aminophenylalanine, para-bromophenylalanine, ortho-chlorophenylalanine, meta-chlorophenylalanine, para-chlorophenylalanine, meta-chlorotyrosine, 3,4-dichlorophenylalanine, 3,4-difluorophenylalanine, 3,5-diiodotyrosine, ortho-fluorophenylalanine, meta-fluorophenylalanine, para-fluorophenylalanine, meta-fluorotyrosine, homophenylalanine, homotyrosine, para-iodophenylalanine, 3-iodotyrosine, meta-methyltyrosine, para-nitrophenylalanine, 3-nitrotyrosine, ortho-phosphotyrosine, pentafluorophenylalanine, and phenylglycine wherein said amino acid residue is in the L configuration;
• m is 1, 2, or 3;
• R14 is hydrogen or protecting group;
• R15 is hydrogen, alkyl or aryl;
• and pharmaceutically acceptable salts, esters, or prodrugs thereof.